•    Long-term effects on cardiovascular morbidity and mortality are unknown.
 
•    LDL-cholesterol lowered about 18%.
 
•    Additive LDL-cholesterol reduction when used in combination with statins.

•    FDA approved Ezetimibe with fenofibrate.

•    Short-term tolerability is similar to placebo. Long-term safety is unknown.
 
•    Not recommended for use in patients with moderate to severe hepatic impairment based on Child-Pugh score. The AUC of ezetimibe
     increased fourfold in patients with moderate hepatic impairment (Child-Pugh score 7 to 9).
 
•    Co-administration with cyclosporine increased ezetimibe blood level 12-fold in one renal transplant patient. Patients on cyclosporine and
      ezetimibe should be monitored carefully.
 
•    Cholestyramine co-administration decreased the mean AUC of total ezetimibe by 55%. Ezetimibe should be given two hours before or
     four hours after bile-acid sequestrants.

•    10 mg daily without regard to meals or time of day.

•    When combined with a statin, ezetimibe may be taken at the same time.

•    Ezetimibe plus simvastatin.
 
•    Ezetimibe 10 mg/simvastatin 10 mg.

•    Ezetimibe 10 mg/simvastatin 20 mg.
 
•    Ezetimibe 10 mg/simvastatin 40 mg.
 
•    Ezetimibe 10 mg/simvastatin 80 mg.

•    Additive effects on LDL-cholesterol reduction.

•    Please refer to information in the ezetimibe and statin sections of this appendix.

•    Please refer to dosing for simvastatin.